FDA RECALLS & COURT ACTIONS: April 1, 1992
CLASS III -- BENZTROPINE MESYLATE TABLETS 0.5 mg, repacked into unit dose containers. Recall number: D-280-2. Lot numbers: 2547-018 9/92, 2547-019 10/92, 2547-020 10/92. Manufacturer: Sidmak Laboratories, Inc., East Hanover, New Jersey. Recalled by: Vangard Labs, Inc., Glasgow, Kentucky (repacker). Firm- initiated recall ongoing. Distribution: Nationwide. Firm estimates 6,800 tablets remain on the market. Reason: Product does not meet USP content uniformity specifications. CLASS III -- CALAMINE LOTION In 4 and 8 ounce bottles, an OTC topical drug. Recall number: D-278- 2. All lots in date. Manufacturer: Barre-National, Inc., Baltimore, Maryland. Recalled by: Manufacturer, by letter Jan. 30, 1992. Firm- initiated recall ongoing. Distribution: Nationwide, Bahamas, Guam. 494,798 units were distributed; firm estimates 9,364 units remain on the market. Reason: Product does not meet stability specifications. CLASS III -- PROMETH WITH CODEINE In 4 and 16 ounce bottles, a Rx drug indicated for the temporary relief of cough and upper respiratory symptoms associated with allergies or the common cold. Recall number: D-279-2. Lot number 03659 EXP 06/92. Manufacturer: Barre-National, Inc., Baltimore, Maryland. Recalled by: Manufacturer, by letter Jan. 30, 1992. Firm- initiated recall ongoing. Distribution: Nationwide. 128,861 units were distributed; firm estimates 24 units remain on the market. Reason: Subpotency of promethazine ingredient.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth